Sionna Therapeutics (NASDAQ:SION – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($3.38) EPS for the quarter, missing the consensus estimate of ($2.68) by ($0.70), Zacks reports.
Sionna Therapeutics Stock Performance
Sionna Therapeutics stock opened at $13.88 on Friday. Sionna Therapeutics has a fifty-two week low of $13.20 and a fifty-two week high of $25.19.
Wall Street Analysts Forecast Growth
SION has been the subject of a number of recent analyst reports. Stifel Nicolaus initiated coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 target price for the company. Guggenheim assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $45.00 price objective on the stock. Finally, TD Cowen began coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a “buy” rating for the company.
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
- Five stocks we like better than Sionna Therapeutics
- How to Buy Cheap Stocks Step by Step
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- How to Use the MarketBeat Excel Dividend Calculator
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
